WSWenying Sun

Wenying Sun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wenying Sun has a total of 50 co-authors. Here are the top co-authors by number of shared publications:

  • Guiping Ren

    Biopharmaceutical Lab, College of Life Science, Northeast Agricultural University, Harbin 150030, China; Research Center of Genetic Engineering of Pharmaceuticals of Heilongjiang Province, Northeast Agricultural University, Harbin 150030, China; Key Laboratory of Agricultural Biological Functional Gene, Northeast Agricultural University, Harbin 150030, China

    3 shared publications
  • Jiechao Yin

    Biopharmaceutical Lab, College of Life Science, Northeast Agricultural University, Harbin 150030, China

    3 shared publications
  • Xiangxiang Wang

    Biopharmaceutical Lab, College of Life Science, Northeast Agricultural University, Harbin 150030, China

    3 shared publications
  • Xiaochen Guo

    Biopharmaceutical Lab, College of Life Science, Northeast Agricultural University, Harbin 150030, China

    3 shared publications
  • Han Zhao

    Biopharmaceutical Lab, College of Life Science, Northeast Agricultural University, Harbin 150030, China

    2 shared publications
  • Lan Wei

    Biopharmaceutical Lab, College of Life Science, Northeast Agricultural University, Harbin 150030, China

    2 shared publications

Latest Publications

  • Robust Graph Neural Networks for Stability Analysis in Dynamic Networks

    by Xin Zhang, Zhen Xu, Yue Liu, Mengfang Sun, Tong Zhou, Wenying Sun

    In the current context of accelerated globalization and digitalization, the complexity and uncertainty of financial markets are increasing, and the identification and prevention of economic risks have become a key link in maintaining the stability of the financial system. Traditional risk identification methods often have limitations because they are difficult to cope with the multi-level and dynamically changing complex relationships in financial networks. With the rapid development of financial technology, graph neural network (GNN) technology, as an emerging deep learning method, has gradually shown great potential in the field of financial risk management. GNN can map transaction behaviors, financial institutions, individuals and their interactive relationships in financial networks into graph structures, and effectively capture potential patterns and abnormal signals in financial data through embedded representation learning. Using this technology, financial institutions can extract valuable information from complex transaction networks, identify hidden dangers or abnormal behaviors that may cause systemic risks in a timely manner, optimize decision-making processes, and improve the accuracy of risk warnings. This paper explores the economic risk identification algorithm based on the GNN algorithm, aiming to provide financial institutions and regulators with more intelligent technical tools to help maintain the security and stability of the financial market. Improving the efficiency of economic risk identification through innovative technical means is expected to further enhance the risk resistance of the financial system and lay the foundation for building a robust global financial system.


  • Open Access

    Development and Evaluation of the Biological Adjuvant Bivalent Vaccine for Preventing Newcastle Disease and Infectious Bursal Disease

    by Xiaochen Guo, Wenying Sun, Changhui Hu, Xiangxiang Wang, Shuang Li, Ruihan Qin, Yixuan Wang, Jinmiao Liu, Zhiqiang Xue, Huijuan Li, et al.

    Newcastle disease (ND) and infectious bursal disease (IBD) are both one of the most economically important infectious diseases, which cause high infection rate and mortality of chickens and restrict the development of the poultry industry. Currently, vaccination is the most effective method to prevent ND and IBD. In this study, the biological adjuvant bivalent vaccine (rClone30-VP2L-chGM-CSF) was developed for preventing ND and IBD. Furthermore, the immune and protective effects of rClone30-VP2L-chGM-CSF were evaluated in specific-pathogen-free chickens. The experimental results indicated that chickens immunized with rClone30-VP2L-chGM-CSF vaccine significantly improved anti-IBDV and anti-NDV antibody titer; the level of CD4+ T, CD8+ T, B+, MHC-II+, and monocyte/macrophagocyte+ cells; the concentrations of IL-1β, IL-4, IL-17, IFN-α, IFN-β, and IFN-γ; and the splenocyte proliferation rate. Anti-NDV antibody titer reached the theoretical protection value of 4log2 at 7days after immunization in chickens of rClone30-VP2L-chGM-CSF group; however, which at 14days after immunization in chickens of rClone30-VP2L and rClone30. These results showed that chickens immunized with rClone30-VP2L-chGM-CSF stimulated stronger immune response than those with the rClone30-VP2L and rClone30. Chickens were challenged with virulent IBDV BC6/85, which were protected in the rClone30-VP2L-chGM-CSF group. Furthermore, IBDV RNA was not measured, and there appeared to be little apoptosis in the bursa of Fabricius in the rClone30-VP2L-chGM-CSF group. Therefore, rClone30-VP2L-chGM-CSF is a promising vaccine candidate against infectious bursal disease virus (IBDV) and newcastle disease virus (NDV), and it provides an idea for developing other poultry vaccines.


  • An immuno-blocking agent targeting IL-1β and IL-17A reduces the lesion of DSS-induced ulcerative colitis in mice

    by Qi Yin, Xuelei Pi, Yuanyuan Jiang, Guiping Ren, Zhihang Liu, Han Liu, Mengxia Wang, Wenying Sun, Siyu Li, Zhenqiu Gao, et al.

    In recent decades when biological agents have flourished, a part of patients suffering from inflammatory bowel disease (IBD) have received the treatment of tumor necrosis factor inhibitors or IL-1 antibodies. This study aims to investigate the anti-colitis effects of bispecific antibody (FL-BsAb1/17) targeting IL-1β and IL-17A comparing with TNF-α soluble receptor medicine etanercept. IBD model in mice was established by drinking 3% DSS (dextran sulfate sodium salt). On the first day of drinking DSS, treatments with etanercept (5 mg/kg) or different doses of FL-BsAb1/17 (1 mg/kg, 5 mg/kg, and 10 mg/kg) were started by intraperitoneal injection every other day. The results demonstrated that FL-BsAb1/17 treatment was more effective than etanercept at the same dose (5 mg/kg) in relieving the typical symptom of ulcerative colitis induced by DSS (such as the severity score and intestinal shortening), and down-regulating the expression of inflammatory factors (IL-17A, IL-6, IL-12, IL-22, IL-1β, IL-23, TNF-α) in the serum and colon. FL-BsAb1/17 could also reduce the degree of intestinal fibrosis. The same dose of FL-BsAb1/17 (5 mg/kg) performed better than etanercept in down-regulating MDA and up-regulating SOD (superoxide dismutase), CAT (catalase), and T-AOC (total antioxidant capacity) in serum. Both FL-BsAb1/17 and etanercept could reduce the transcription of Bax and increase the transcription of Bcl-2 and slow down apoptosis in colitis colon tissue. We conclude that the blocking of IL-1β and IL-17A can inhibit DSS-induced ulcerative colitis and FL-BsAb1/17 may have potential to become a new dual-target candidate for colitis treatment.


  • Development and evaluation of a recombinant VP2 neutralizing epitope antigen vaccine candidate for infectious bursal disease virus

    by Xiaochen Guo, Wenying Sun, Lan Wei, Xiangxiang Wang, Yimeng Zou, Yingying Zhang, Shuai Li, Nan Wang, Ming Jiang, Han Zhao, et al.

    Infectious bursal disease (IBD) is one of the most economically important infectious diseases. Currently, vaccination is the most effective method to prevent IBD. Medium‐virulence vaccines can damage the bursa of Fabricius and result in immunosuppression. Therefore, it is essential to develop a safe and effective vaccine against infectious bursal disease virus (IBDV). In this study, the five neutralizing epitopes of the IBDV VP2 protein were confirmed by neutralizing single chain variable fragment antibodies. Then, the neutralizing epitopes antigen (NEA) protein was constructed with five neutralizing epitopes and expressed by pET‐27b. Furthermore, the immune effect and protective immunity of the NEA protein with the following adjuvants were evaluated in specific‐pathogen‐free chickens: oil emulsion adjuvant (OEA), double emulsion adjuvant (DEA), granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) adjuvant, and complete Freund’s adjuvant (CFA). The experimental results demonstrated that chickens immunized with NEA vaccines elicited stronger humoral and/or cellular immune responses and inflammatory responses than those in the NEA protein group. Chickens were protected in OEA, CFA, and GM‐CSF adjuvant groups, which were challenged with virulent IBDV BC6/85. Furthermore, IBDV RNA was not measured, and there appeared to be little apoptosis in the bursa of Fabricius based on TUNEL histology and the expression of Bax and Bcl‐2 in the OEA, CFA, and GM‐CSF adjuvant groups. Based on the experimental results, the advantages and disadvantages of adjuvants, and industrial production methods, GM‐CSF was found to be the optimal adjuvant. Therefore, NEA with GM‐CSF adjuvant is a promising vaccine candidate against IBDV, and it provides a framework for developing other vaccines against infectious viral diseases.


  • The immune enhancement effects of recombinant NDV expressing chicken granulocyte-macrophage colony-stimulating factor on the different avian influenza vaccine subtypes

    by Xiaochen Guo, Teng Zhang, Xiangxiang Wang, Han Su, Wenying Sun, Yunye Liu, Kai Kang, Tianyan Liu, Shan Jiang, Yaoqun Wang, et al.

    Avian influenza is an acute and highly contagious infectious disease that is caused by the influenza virus. Avian influenza has been widely spread all over the world, has caused property loss and has threatened human life and security. In this study, the recombinant plasmid rClone30‐chGM‐CSF was constructed and rescued to the recombinant virus rClone30‐chGM‐CSF successfully. After 8 days of immunization with the recombinant virus, the titer of NDV HI (hemagglutination inhibition) antibodies in SPF chickens reached its peak. The average titer of the rClone30‐chGM‐CSF group reached 6 log2 and was significantly higher than the protection critical value of 4 log2; the titers of the rClone30 group and the blank group were 2.86 log2 and 1 log2, respectively, indicating that the recombinant virus can effectively improve the NDV antibody titer. Then, SPF chickens were co‐immunized with the recombinant virus and with three different vaccine subtypes of inactivated avian influenza. The results indicated that the SPF chickens that were immunized with the vaccine plus rClone30‐chGM‐CSF showed significantly higher avian influenza antibody levels than those in the single vaccine groups. Furthermore, the SPF chickens in the vaccine plus rClone30‐chGM‐CSF group elicited stronger CD4+ T and CD8+ T cell proliferative responses and also had upregulated transcriptional levels of interleukin‐1β (IL‐1β), IL‐4, IL‐6 and IL‐17 compared with those in the single vaccine groups. This study has shown that the recombinant virus expressing chicken granulocyte‐macrophage colony stimulating factor (chGM‐CSF) can be used not only as an NDV vaccine to effectively improve the titer of NDV antibodies but also as a biological adjuvant to enhance the immune effects of the avian influenza vaccine. Therefore, this recombinant virus can also be used as a biological adjuvant for other poultry vaccines.